KR102811519B1 - 간세포성 암종의 치료를 위한 조합 요법 - Google Patents

간세포성 암종의 치료를 위한 조합 요법 Download PDF

Info

Publication number
KR102811519B1
KR102811519B1 KR1020207022999A KR20207022999A KR102811519B1 KR 102811519 B1 KR102811519 B1 KR 102811519B1 KR 1020207022999 A KR1020207022999 A KR 1020207022999A KR 20207022999 A KR20207022999 A KR 20207022999A KR 102811519 B1 KR102811519 B1 KR 102811519B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acid
acceptable salt
lenvatinib
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207022999A
Other languages
English (en)
Korean (ko)
Other versions
KR20200121302A (ko
Inventor
아난드 셀바라즈
피터 스미스
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Priority to KR1020257016389A priority Critical patent/KR20250073570A/ko
Publication of KR20200121302A publication Critical patent/KR20200121302A/ko
Application granted granted Critical
Publication of KR102811519B1 publication Critical patent/KR102811519B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020207022999A 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법 Active KR102811519B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257016389A KR20250073570A (ko) 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862615848P 2018-01-10 2018-01-10
US62/615,848 2018-01-10
PCT/US2019/012886 WO2019139977A1 (en) 2018-01-10 2019-01-09 Combination therapies for the treatment of hepatocellular carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257016389A Division KR20250073570A (ko) 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법

Publications (2)

Publication Number Publication Date
KR20200121302A KR20200121302A (ko) 2020-10-23
KR102811519B1 true KR102811519B1 (ko) 2025-05-22

Family

ID=65411938

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207022999A Active KR102811519B1 (ko) 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법
KR1020257016389A Pending KR20250073570A (ko) 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257016389A Pending KR20250073570A (ko) 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법

Country Status (13)

Country Link
US (1) US11833119B2 (https=)
EP (2) EP4667005A3 (https=)
JP (2) JP7352569B2 (https=)
KR (2) KR102811519B1 (https=)
CN (1) CN111787922A (https=)
AU (1) AU2019206480A1 (https=)
BR (1) BR112020014112A2 (https=)
CA (1) CA3088292A1 (https=)
IL (1) IL275981A (https=)
MA (1) MA51570A (https=)
MX (1) MX2020007375A (https=)
SG (1) SG11202006617RA (https=)
WO (1) WO2019139977A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533903A (ja) * 2020-05-15 2023-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法
JP2025520303A (ja) * 2022-05-30 2025-07-03 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 癌治療用の医薬組み合わせ物および医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160089365A1 (en) 2014-09-25 2016-03-31 Eisai R&D Management Co., Ltd. Immunostimulatory compound
WO2017196854A1 (en) 2016-05-10 2017-11-16 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
KR100804566B1 (ko) 2003-12-25 2008-02-20 에자이 알앤드디 매니지먼트 가부시키가이샤 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의 결정 및 이들의 제조 방법
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2809312A1 (en) 2012-01-31 2014-12-10 Novartis AG Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
BR112015029386B1 (pt) 2013-06-26 2023-11-14 Eisai R&D Management Co., Ltd. Uso de eribulina e lenvatinibe como terapia de combinação e kit
PH12016500676B1 (en) * 2013-10-18 2022-07-20 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
HRP20210319T1 (hr) * 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije inhibitora fgfr i inhibitora igf1r
KR102548229B1 (ko) 2015-04-14 2023-06-27 에자이 알앤드디 매니지먼트 가부시키가이샤 결정질 fgfr4 억제제 화합물 및 그의 용도
CN107304188A (zh) 2016-04-20 2017-10-31 成都融科博海科技有限公司 一种氘代激酶选择性抑制剂及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160089365A1 (en) 2014-09-25 2016-03-31 Eisai R&D Management Co., Ltd. Immunostimulatory compound
WO2017196854A1 (en) 2016-05-10 2017-11-16 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation

Also Published As

Publication number Publication date
IL275981A (en) 2020-08-31
JP7665700B2 (ja) 2025-04-21
US11833119B2 (en) 2023-12-05
MX2020007375A (es) 2020-11-09
EP4667005A2 (en) 2025-12-24
JP2021512140A (ja) 2021-05-13
MA51570A (fr) 2020-11-18
RU2020126673A3 (https=) 2022-04-19
CN111787922A (zh) 2020-10-16
EP3737377A1 (en) 2020-11-18
EP4667005A3 (en) 2026-02-18
WO2019139977A1 (en) 2019-07-18
US20200360371A1 (en) 2020-11-19
AU2019206480A1 (en) 2020-08-27
KR20200121302A (ko) 2020-10-23
BR112020014112A2 (pt) 2020-12-01
EP3737377B1 (en) 2025-10-08
JP7352569B2 (ja) 2023-09-28
KR20250073570A (ko) 2025-05-27
JP2023175825A (ja) 2023-12-12
RU2020126673A (ru) 2022-02-10
CA3088292A1 (en) 2019-07-18
SG11202006617RA (en) 2020-08-28

Similar Documents

Publication Publication Date Title
EP3503923B1 (en) Combination therapies for the treatment of hepatocellular carcinoma
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
KR102517650B1 (ko) 유방암의 치료를 위한 조합물 요법
US20110251239A1 (en) Combination therapy for the treatment of dementia
JP2022160654A (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
KR20220029717A (ko) 항암 화합물 e7766의 치료 순응도 향상을 위한 시스템
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200810

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20201019

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220107

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240620

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250218

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250519

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250519

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250520

End annual number: 3

Start annual number: 1

PG1601 Publication of registration